What is the success rate of stem cell therapy for Alzheimer's Disease?
No defensible pooled success rate exists across heterogeneous cell and exosome products. Review the exact trial's cognitive and functional endpoints, comparator, baseline stage, missing data, caregiver measures, adverse events and absolute effect.
What the evidence shows for Alzheimer's Disease
Human cell and exosome evidence remains investigational, product-specific and generally insufficient to establish clinical benefit. Biomarker movement cannot replace validated cognitive and functional outcomes, a comparator and adequate follow-up. The FDA patient page states that regenerative medicine therapies are not approved in the United States to treat Alzheimer's disease. Current established and approved options should be reviewed with a dementia specialist.
Am I a candidate? → · Alzheimer's Disease: full overview → · Alzheimer's Disease cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Alzheimer's Disease: cell-therapy evidence and registered trials
- How much does stem cell therapy for Alzheimer's Disease cost? (2026)
- Alzheimer's Disease stem cell therapy — your questions answered (2026)
- Alzheimer's Disease: cell-therapy evidence by therapy class
- MSC vs exosomes for Alzheimer's Disease: what the registries show